Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAST-LDL: Recaticimab in Acute Ischemic Stroke
NCT07002476Phase 3Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of recaticimab in ischemic stroke, sponsored by Shanghai East Hospital. Started Jun 2025; status: recruiting.
02
Drugs
recaticimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07002476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002476.